TY - JOUR T1 - Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 763 LP - 770 DO - 10.1097/IGC.0b013e31821b2669 VL - 21 IS - 4 AU - Jonathan A. Ledermann AU - Christian Marth AU - Mark S. Carey AU - Michael Birrer AU - David D.L. Bowtell AU - Stan Kaye AU - Iain McNeish AU - Amit Oza AU - Giovanni Scambia AU - Gordon Rustin AU - Frederick B. Stehman AU - David Gershenson AU - Gillian Thomas AU - Els Berns AU - Antonio Casado AU - Nelleke Ottevanger AU - Felix Hilpert AU - Byoung-Gie Kim AU - Aikou Okamoto AU - Monica Bacon AU - Henry Kitchener AU - Gavin C.E. Stuart Y1 - 2011/04/01 UR - http://ijgc.bmj.com/content/21/4/763.abstract N2 - There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference. ER -